Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis
出版年份 2017 全文链接
标题
Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis
作者
关键词
-
出版物
INTERNATIONAL JOURNAL OF CANCER
Volume 140, Issue 12, Pages 2805-2819
出版商
Wiley
发表日期
2017-03-15
DOI
10.1002/ijc.30691
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Low-dose Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibition of EGFR Mutation-positive Lung Cancer: Therapeutic Benefits and Associations Between Dosage, Efficacy and Body Surface Area
- (2016) Ryosuke Hirano et al. Asian Pacific Journal of Cancer Prevention
- Serum Neuron-Specific Enolase Levels Predict the Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations
- (2016) Koung Jin Suh et al. Clinical Lung Cancer
- Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L
- (2016) Yoshiko Urata et al. JOURNAL OF CLINICAL ONCOLOGY
- Five-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs
- (2016) Jessica J. Lin et al. Journal of Thoracic Oncology
- Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
- (2016) Keunchil Park et al. LANCET ONCOLOGY
- Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors
- (2016) Jumpei Kashima et al. MEDICAL ONCOLOGY
- Gefitinib, Erlotinib and Chemotherapy as Second-Line Treatment for Patient with Advanced Non-Small Lung Cancer (NSCLC)
- (2016) M Yang et al. VALUE IN HEALTH
- Genetic Association of Curative and Adverse Reactions to Tyrosine Kinase Inhibitors in Chinese advanced Non-Small Cell Lung Cancer patients
- (2016) Yunfeng Ruan et al. Scientific Reports
- Study of efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib for advanced non-small cell lung cancer patients with secondary drug resistance: A single center, single arm, phase II clinical trial
- (2016) Yanzhe Zhu et al. Thoracic Cancer
- Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations
- (2015) Eva Regina Haspinger et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Cutaneous adverse events of epidermal growth factor receptor inhibitors: A retrospective review of 99 cases
- (2015) Vasanop Vachiramon et al. Indian Journal of Dermatology Venereology & Leprology
- Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial
- (2015) Jean-Charles Soria et al. LANCET ONCOLOGY
- miR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type
- (2015) Jiayu Li et al. Oncotarget
- Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment
- (2014) Gui-Nan Lin et al. Asia-Pacific Journal of Clinical Oncology
- EGFR–TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation
- (2014) Dong-Hoe Koo et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Management of Nonhematologic Toxicities Associated With Different EGFR-TKIs in Advanced NSCLC: A Comparison Analysis
- (2014) Antonio Passaro et al. Clinical Lung Cancer
- Epithelial phenotype as a predictive marker for response to EGFR-TKIs in non-small cell lung cancer patients with wild-type EGFR
- (2014) Shengxiang Ren et al. INTERNATIONAL JOURNAL OF CANCER
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non–Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor
- (2014) June-Koo Lee et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancer
- (2014) Sung Hoon Sim et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non–Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor Receptor Mutation in Either Exon 19 or 21
- (2014) Sung Hee Lim et al. Journal of Thoracic Oncology
- Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations
- (2014) Benjamin Haaland et al. Journal of Thoracic Oncology
- Survival Outcome Assessed According to Tumor Response and Shrinkage Pattern in Patients with EGFR Mutation–Positive Non–Small-Cell Lung Cancer Treated with Gefitinib or Erlotinib
- (2014) Masayuki Takeda et al. Journal of Thoracic Oncology
- Lifestyle risks exposure and response predictor of gefitinib in patients with non-small cell lung cancer
- (2014) Hongyan Ying et al. MEDICAL ONCOLOGY
- Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations
- (2014) Wenhua Liang et al. PLoS One
- Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects
- (2013) Giuseppe Bronte et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis
- (2013) Chee Khoon Lee et al. JNCI-Journal of the National Cancer Institute
- Erlotinib Versus Gefitinib for Control of Leptomeningeal Carcinomatosis in Non–Small-Cell Lung Cancer
- (2013) Eunyoung Lee et al. Journal of Thoracic Oncology
- Routine EGFR Molecular Analysis in Non-Small-Cell Lung Cancer Patients is Feasible: Exons 18–21 Sequencing Results of 753 Patients and Subsequent Clinical Outcomes
- (2013) Myriam Locatelli-Sanchez et al. LUNG
- Quantitative Chemical Proteomics Profiling Differentiates Erlotinib from Gefitinib in EGFR Wild-Type Non-Small Cell Lung Carcinoma Cell Lines
- (2013) A. Augustin et al. MOLECULAR CANCER THERAPEUTICS
- Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer
- (2012) Tomohiro Suzumura et al. BMC CANCER
- Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer
- (2012) Yosuke Togashi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer
- (2012) Yu-Yun Shao et al. EUROPEAN JOURNAL OF CANCER
- Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation
- (2012) S.J. Park et al. LUNG CANCER
- Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis
- (2012) Tsukasa Yoshida et al. MEDICAL ONCOLOGY
- Prognosis in Patients with Non-Small Cell Lung Cancer Who Received Erlotinib Treatment and Subsequent Dose Reduction due to Skin Rash
- (2012) Naoki Takashima et al. ONKOLOGIE
- Low-Dose Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations
- (2011) Hironori Satoh et al. Journal of Thoracic Oncology
- Differences in adverse events between 250mg daily gefitinib and 150mg daily erlotinib in Japanese patients with non-small cell lung cancer
- (2011) Yosuke Togashi et al. LUNG CANCER
- Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy
- (2011) Seung Tae Kim et al. LUNG CANCER
- Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib
- (2011) Vince D. Cataldo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy
- (2010) Seung Tae Kim et al. CANCER
- Erlotinib at a Dose of 25 mg Daily for Non-small Cell Lung Cancers with EGFR Mutations
- (2010) Wee-Lee Yeo et al. Journal of Thoracic Oncology
- Comparison of the Incidence and Pattern of Interstitial Lung Disease During Erlotinib and Gefitinib Treatment in Japanese Patients with Non-small Cell Lung Cancer: The Okayama Lung Cancer Study Group Experience
- (2010) Katsuyuki Hotta et al. Journal of Thoracic Oncology
- Different Efficacies of Erlotinib and Gefitinib in Taiwanese Patients with Advanced Non-small Cell Lung Cancer: A Retrospective Multicenter Study
- (2010) Wen-Chien Fan et al. Journal of Thoracic Oncology
- Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations
- (2010) Jenn-Yu Wu et al. LUNG CANCER
- Pemetrexed versus Gefitinib versus Erlotinib in Previously Treated Patients with Non-Small Cell Lung Cancer
- (2010) Junshik Hong et al. KOREAN JOURNAL OF INTERNAL MEDICINE
- Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
- (2009) Ivette F Emery et al. BMC CANCER
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- (2008) D Li et al. ONCOGENE
- Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer
- (2007) Sanjay Popat et al. LUNG CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started